TipRanks
Advertisement
Advertisement
Hemab Therapeutics presents sutacimig data at ISTH Congress
PremiumThe FlyHemab Therapeutics presents sutacimig data at ISTH Congress
2M ago
Hemab Therapeutics price target raised to $47 from $39 at Jefferies
Premium
The Fly
Hemab Therapeutics price target raised to $47 from $39 at Jefferies
2M ago
Hemab Therapeutics price target raised to $55 from $42 at Wedbush
Premium
The Fly
Hemab Therapeutics price target raised to $55 from $42 at Wedbush
2M ago
PremiumRatingsJefferies Reiterates Buy on Hemab Therapeutics, Maintains $39 Price Target on VWD Opportunity and Differentiated Mechanism
4M ago
Jefferies sees positive readthroughs to Hemab Therapeutics from Incyte deal
Premium
The Fly
Jefferies sees positive readthroughs to Hemab Therapeutics from Incyte deal
4M ago
Opening Day: SpaceX submits S-1 for Nasdaq IPO
Premium
The Fly
Opening Day: SpaceX submits S-1 for Nasdaq IPO
4M ago
Hemab Therapeutics initiated with a Buy at Goldman Sachs
PremiumThe FlyHemab Therapeutics initiated with a Buy at Goldman Sachs
4M ago
Premium
Ratings
Analyst Initiates Buy on Hemab, Citing Differentiated Bleeding-Disorder Pipeline and Multi‑Billion‑Dollar Peak Sales Potential
4M ago
Opening Day: Pershing Square listings open soft in market debut
Premium
The Fly
Opening Day: Pershing Square listings open soft in market debut
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100